p38 mitogen-activated protein kinase determines the susceptibility to cigarette smoke-induced emphysema in mice

BMC Pulmonary Medicine

Michiaki Mishima¹  Toyohiro Hirai¹  Shigeo Muro¹  Emiko Ogawa¹  Atsuyasu Sato¹  Naoya Tanabe¹  Hirofumi Kiyokawa¹  Yuma Hoshino¹  Satoshi Marumo¹ 

[1] Department of Respiratory Medicine, Graduate School of Medicine, Kyoto University, 54 Kawahara-cho, Shogoin, Sakyo-ku, Kyoto, Japan

关键词: Molecular targeted therapy;    Signal transduction;    Disease susceptibility;    Animal model;    Chronic obstructive pulmonary disease;   

Others  :  862948
DOI  :  10.1186/1471-2466-14-79

 received in 2013-06-12, accepted in 2014-04-23,  发布年份 2014

【 摘 要 】

Background

There is a need for agents that suppress inflammation and progression of chronic obstructive pulmonary disease. p38 mitogen-activated protein kinase (p38 MAPK) has been associated with this disorder, and several inhibitors of this cascade are in clinical trials for its treatment, but their efficacy and utility are unknown. This study evaluated the relationship between p38 MAPK activation and susceptibility to cigarette smoke (CS)-induced emphysema, and whether its inhibition ameliorated the lung inflammation and injury in murine models of cigarette smoke exposure.

Methods

In acute and chronic CS exposure, the activation and expression of p38 MAPK in the lungs, as well as lung inflammation and injury (proteinase production, apoptosis, and oxidative DNA damage), were compared between two mouse strains: C57BL/6 (emphysema-susceptible) and NZW (emphysema-resistant). The selective p38 MAPK inhibitor SB203580 (45 mg/kg) was administrated intra-peritoneally to C57BL/6 mice, to examine whether it ameliorated cigarette smoke-induced lung inflammation and injury.

Results

Acute CS-induced lung inflammation (neutrophil infiltration, mRNA expressions of TNF-α and MIP-2), proteinase expression (MMP-12 mRNA), apoptosis, and oxidative DNA damage were significantly lower in NZW than C57BL/6 mice. p38 MAPK was significantly activated and up-regulated by both acute and chronic CS exposure in C57BL/6 but not NZW mice. mRNA expression of p38 MAPK was also upregulated in C57BL/6 by chronic CS exposure and tended to be constitutively suppressed in NZW mice. SB203580 significantly attenuated lung inflammation (neutrophil infiltration, mRNA expressions of TNF-α and MIP-2, protein levels of KC, MIP-1α, IL-1β, and IL-6), proteinase expression (MMP-12 mRNA), oxidative DNA damage, and apoptosis caused by acute CS exposure.

Conclusions

Cigarette smoke activated p38 MAPK only in mice that were susceptible to cigarette smoke-induced emphysema. Its selective inhibition ameliorated lung inflammation and injury in a murine model of cigarette smoke exposure. p38 MAPK pathways are a possible molecular target for the treatment of chronic obstructive pulmonary disease.

【 授权许可】

   
2014 Marumo et al.; licensee BioMed Central Ltd.

【 图 表 】

【 参考文献 】

• [1]Daher M: Overview of the World Health Report 2000 Health systems: improving performance. J Med Liban 2001, 49(1):22-24.
• [2]Lopez AD, Shibuya K, Rao C, Mathers CD, Hansell AL, Held LS, Schmid V, Buist S: Chronic obstructive pulmonary disease: current burden and future projections. Eur Respir J 2006, 27(2):397-412.
• [3]Loppow D, Schleiss MB, Kanniess F, Taube C, Jorres RA, Magnussen H: In patients with chronic bronchitis a four week trial with inhaled steroids does not attenuate airway inflammation. Respir Med 2001, 95(2):115-121.
• [4]Barnes PJ, Shapiro SD, Pauwels RA: Chronic obstructive pulmonary disease: molecular and cellular mechanisms. Eur Respir J 2003, 22(4):672-688.
• [5]Nakamura T, Lozano PR, Ikeda Y, Iwanaga Y, Hinek A, Minamisawa S, Cheng CF, Kobuke K, Dalton N, Takada Y, Tashiro K, Ross J Jr, Honjo T, Chien KR: Fibulin-5/DANCE is essential for elastogenesis in vivo. Nature 2002, 415(6868):171-175.
• [6]Teramoto S, Fukuchi Y, Uejima Y, Teramoto K, Oka T, Orimo H: A novel model of senile lung: senescence-accelerated mouse (SAM). Am J Respir Crit Care Med 1994, 150(1):238-244.
• [7]Celli BR, Thomas NE, Anderson JA, Ferguson GT, Jenkins CR, Jones PW, Vestbo J, Knobil K, Yates JC, Calverley PM: Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study. Am J Respir Crit Care Med 2008, 178(4):332-338.
• [8]Anthonisen NR, Connett JE, Kiley JP, Altose MD, Bailey WC, Buist AS, Conway WA Jr, Enright PL, Kanner RE, O’Hara P: Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1. The lung health study. JAMA 1994, 272(19):1497-1505.
• [9]Burge PS, Calverley PM, Jones PW, Spencer S, Anderson JA, Maslen TK: Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. BMJ 2000, 320(7245):1297-1303.
• [10]Pauwels RA, Lofdahl CG, Laitinen LA, Schouten JP, Postma DS, Pride NB, Ohlsson SV: Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. European respiratory society study on chronic obstructive pulmonary disease. N Engl J Med 1999, 340(25):1948-1953.
• [11]Vestbo J, Sorensen T, Lange P, Brix A, Torre P, Viskum K: Long-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 1999, 353(9167):1819-1823.
• [12]Culpitt SV, Maziak W, Loukidis S, Nightingale JA, Matthews JL, Barnes PJ: Effect of high dose inhaled steroid on cells, cytokines, and proteases in induced sputum in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1999, 160(5 Pt 1):1635-1639.
• [13]Ito K, Lim S, Caramori G, Chung KF, Barnes PJ, Adcock IM: Cigarette smoking reduces histone deacetylase 2 expression, enhances cytokine expression, and inhibits glucocorticoid actions in alveolar macrophages. FASEB J 2001, 15(6):1110-1112.
• [14]Rabe KF, Bateman ED, O’Donnell D, Witte S, Bredenbroker D, Bethke TD: Roflumilast–an oral anti-inflammatory treatment for chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 2005, 366(9485):563-571.
• [15]Rennard SI, Fogarty C, Kelsen S, Long W, Ramsdell J, Allison J, Mahler D, Saadeh C, Siler T, Snell P, Korenblat P, Smith W, Kaye M, Mandel M, Andrews C, Prabhu R, Donohue JF, Watt R, Lo KH, Schlenker-Herceg R, Barnathan ES, Murray J, COPD Investigators: The safety and efficacy of infliximab in moderate to severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007, 175(9):926-934.
• [16]Chopra P, Kanoje V, Semwal A, Ray A: Therapeutic potential of inhaled p38 mitogen-activated protein kinase inhibitors for inflammatory pulmonary diseases. Expert Opin Investig Drugs 2008, 17(10):1411-1425.
• [17]Mercer BA, D’Armiento JM: Emerging role of MAP kinase pathways as therapeutic targets in COPD. Int J Chron Obstruct Pulmon Dis 2006, 1(2):137-150.
• [18]Yong HY, Koh MS, Moon A: The p38 MAPK inhibitors for the treatment of inflammatory diseases and cancer. Expert Opin Investig Drugs 2009, 18(12):1893-1905.
• [19]Renda T, Baraldo S, Pelaia G, Bazzan E, Turato G, Papi A, Maestrelli P, Maselli R, Vatrella A, Fabbri LM, Zuin R, Marsico SA, Saetta M: Increased activation of p38 MAPK in COPD. Eur Respir J 2008, 31(1):62-69.
• [20]Medicherla S, Fitzgerald MF, Spicer D, Woodman P, Ma JY, Kapoun AM, Chakravarty S, Dugar S, Protter AA, Higgins LS: p38alpha-selective mitogen-activated protein kinase inhibitor SD-282 reduces inflammation in a subchronic model of tobacco smoke-induced airway inflammation. J Pharmacol Exp Ther 2008, 324(3):921-929.
• [21]Kasahara Y, Tuder RM, Cool CD, Lynch DA, Flores SC, Voelkel NF: Endothelial cell death and decreased expression of vascular endothelial growth factor and vascular endothelial growth factor receptor 2 in emphysema. Am J Respir Crit Care Med 2001, 163(3 Pt 1):737-744.
• [22]Laurell CBES: The electrophoretic α-1-globulin pattern of serum in α-1-antitrypsin deficiency. Scand J Clin Lab Invest 1963, 15:132-140.
• [23]MacNee W, Rahman I: Is oxidative stress central to the pathogenesis of chronic obstructive pulmonary disease? Trends Mol Med 2001, 7(2):55-62.
• [24]Sato A, Hoshino Y, Hara T, Muro S, Nakamura H, Mishima M, Yodoi J: Thioredoxin-1 ameliorates cigarette smoke-induced lung inflammation and emphysema in mice. J Pharmacol Exp Ther 2008, 325(2):380-388.
• [25]Matthew E, Warden G, Dedman J: A murine model of smoke inhalation. Am J Physiol Lung Cell Mol Physiol 2001, 280(4):L716-L723.
• [26]Sato A, Hirai T, Imura A, Kita N, Iwano A, Muro S, Nabeshima Y, Suki B, Mishima M: Morphological mechanism of the development of pulmonary emphysema in klotho mice. Proc Natl Acad Sci U S A 2007, 104(7):2361-2365.
• [27]Chang L, Karin M: Mammalian MAP kinase signalling cascades. Nature 2001, 410(6824):37-40.
• [28]Badger AM, Bradbeer JN, Votta B, Lee JC, Adams JL, Griswold DE: Pharmacological profile of SB 203580, a selective inhibitor of cytokine suppressive binding protein/p38 kinase, in animal models of arthritis, bone resorption, endotoxin shock and immune function. J Pharmacol Exp Ther 1996, 279(3):1453-1461.
• [29]Badger AM, Griswold DE, Kapadia R, Blake S, Swift BA, Hoffman SJ, Stroup GB, Webb E, Rieman DJ, Gowen M, Boehm JC, Adams JL, Lee JC: Disease-modifying activity of SB 242235, a selective inhibitor of p38 mitogen-activated protein kinase, in rat adjuvant-induced arthritis. Arthritis Rheum 2000, 43(1):175-183.
• [30]Jackson JR, Bolognese B, Hillegass L, Kassis S, Adams J, Griswold DE, Winkler JD: Pharmacological effects of SB 220025, a selective inhibitor of P38 mitogen-activated protein kinase, in angiogenesis and chronic inflammatory disease models. J Pharmacol Exp Ther 1998, 284(2):687-692.
• [31]Yao H, Edirisinghe I, Rajendrasozhan S, Yang SR, Caito S, Adenuga D, Rahman I: Cigarette smoke-mediated inflammatory and oxidative responses are strain-dependent in mice. Am J Physiol Lung Cell Mol Physiol 2008, 294(6):L1174-L1186.
• [32]Keyse SM: Protein phosphatases and the regulation of mitogen-activated protein kinase signalling. Curr Opin Cell Biol 2000, 12(2):186-192.
• [33]Kitahara T, Kiryu S, Ohno K, Morita N, Kubo T, Kiyama H: Up-regulation of ERK (MAP kinase) and MEK (MAP kinase) transcription after rat facial nerve transection. Neurosci Res 1994, 20(3):275-280.
• [34]Wright JL, Cosio M, Churg A: Animal models of chronic obstructive pulmonary disease. Am J Physiol Lung Cell Mol Physiol 2008, 295(1):L1-L15.
• [35]Chen ZH, Kim HP, Ryter SW, Choi AM: Identifying targets for COPD treatment through gene expression analyses. Int J Chron Obstruct Pulmon Dis 2008, 3(3):359-370.
• [36]Chung KF: p38 mitogen-activated protein kinase pathways in asthma and COPD. Chest 2011, 139(6):1470-1479.
• [37]Barnes PJ: The cytokine network in chronic obstructive pulmonary disease. Am J Respir Cell Mol Biol 2009, 41(6):631-638.
• [38]Volpi G, Facchinetti F, Moretto N, Civelli M, Patacchini R: Cigarette smoke and alpha, beta-unsaturated aldehydes elicit VEGF release through the p38 MAPK pathway in human airway smooth muscle cells and lung fibroblasts. Br J Pharmacol 2011, 163(3):649-661.
• [39]Schweitzer KS, Hatoum H, Brown MB, Gupta M, Justice MJ, Beteck B, Van Demark M, Gu Y, Presson RG Jr, Hubbard WC, Petrache I: Mechanisms of lung endothelial barrier disruption induced by cigarette smoke: role of oxidative stress and ceramides. Am J Physiol Lung Cell Mol Physiol 2011, 301(6):L836-L846.
• [40]Hommes D, van den Blink B, Plasse T, Bartelsman J, Xu C, Macpherson B, Tytgat G, Peppelenbosch M, van Deventer S: Inhibition of stress-activated MAP kinases induces clinical improvement in moderate to severe Crohn’s disease. Gastroenterology 2002, 122(1):7-14.
• [41]Nikas SN, Drosos AA: SCIO-469 Scios Inc. Curr Opin Investig Drugs 2004, 5(11):1205-1212.
• [42]MacNee W, Allan RJ, Jones I, de Salvo MC, Tan LF: Efficacy and safety of the oral p38 inhibitor PH-797804 in chronic obstructive pulmonary disease: a randomised clinical trial. Thorax 2013, 68(8):738-745.
• [43]Singh D: P38 inhibition in COPD; cautious optimism. Thorax 2013, 68(8):705-706.
• [44]Kotlyarov A, Neininger A, Schubert C, Eckert R, Birchmeier C, Volk HD, Gaestel M: MAPKAP kinase 2 is essential for LPS-induced TNF-alpha biosynthesis. Nat Cell Biol 1999, 1(2):94-97.
• [45]Guerassimov A, Hoshino Y, Takubo Y, Turcotte A, Yamamoto M, Ghezzo H, Triantafillopoulos A, Whittaker K, Hoidal JR, Cosio MG: The development of emphysema in cigarette smoke-exposed mice is strain dependent. Am J Respir Crit Care Med 2004, 170(9):974-980.
• [46]Turato G, di Stefano A, Maestrelli P, Mapp CE, Ruggieri MP, Roggeri A, Fabbri LM, Saetta M: Effect of smoking cessation on airway inflammation in chronic bronchitis. Am J Respir Crit Care Med 1995, 152(4 Pt 1):1262-1267.